Hyperliquid Strategies INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Lawrence E. Leibowitz, a Director at Hyperliquid Strategies Inc., received 2,117 shares of common stock as compensation.
Eric S. Rosengren, a Director at Hyperliquid Strategies Inc., acquired 4,764 shares of common stock as compensation on July 1, 2026.
Director Thomas C. King acquired 4,764 shares of common stock in Hyperliquid Strategies Inc. as compensation.
Nailesh Bhatt, a Director at Hyperliquid Strategies Inc., acquired 1,588 shares of common stock as compensation.
Hyperliquid Strategies Inc. reports that Chief Operating Officer Jeroen Nieuwkoop, through SBR Limited, acquired 421,623 restricted stock units (RSUs) on June 23, 2026, as part of an executive placement agreement.
Hyperliquid Strategies Inc. CFO, Brett Douglas Beldner, was granted 421,623 restricted stock units on May 5, 2026, as part of his employment agreement.
Director Nailesh Bhatt acquired 2,455 shares of Hyperliquid Strategies Inc. common stock as compensation in lieu of cash.
Director Eric S. Rosengren acquired 7,367 shares of Hyperliquid Strategies Inc. common stock as compensation in lieu of cash.
Director Thomas C. King acquired 7,367 shares of Hyperliquid Strategies Inc. common stock as compensation in lieu of cash.
Director Lawrence E. Leibowitz acquired 3,274 shares of Hyperliquid Strategies Inc. common stock as compensation in lieu of cash.
Hyperliquid Strategies Inc. CEO David Ira Schamis acquired 40,789 restricted stock units, increasing his beneficial ownership.
Hyperliquid Strategies Inc. Director Jeffrey Tuder reported the acquisition of 40,789 restricted stock units and holds 8,188 shares indirectly.
Hyperliquid Strategies Inc. Director Albert D. Dyrness acquired 40,789 restricted stock units, vesting over three years.
Hyperliquid Strategies Inc. director Robert E. Diamond Jr. received a grant of 40,789 restricted stock units vesting over three years.
Hyperliquid Strategies Inc. director Nailesh Bhatt received a grant of 40,789 restricted stock units, vesting over three years.
Hyperliquid Strategies Inc. Director Eric S. Rosengren acquired 40,789 restricted stock units, increasing his beneficial ownership to 64,669 shares.
Hyperliquid Strategies Inc. Director Thomas C. King was granted 40,789 restricted stock units, vesting over three years.
Lawrence E. Leibowitz, a Director and 10% Owner of Hyperliquid Strategies Inc., acquired 40,789 shares of common stock.
Hyperliquid Strategies Inc. COO Jeroen Nieuwkoop received 31,840 common shares following the company's business combination.
Hyperliquid Strategies Director Albert Dyrness acquired 882 shares of common stock following the company's business combination with Sonnet BioTherapeutics.
Hyperliquid Strategies Inc. Director Robert E. Diamond Jr. received 636,800 shares of common stock following the company's business combination with Sonnet BioTherapeutics Holdings, Inc.
Hyperliquid Strategies Inc. Director Eric S. Rosengren acquired 23,880 shares of common stock following a business combination.
Hyperliquid Strategies Director Thomas C. King acquired 23,880 shares of common stock following the company's business combination with Sonnet BioTherapeutics.
Hyperliquid Strategies Inc. director Nailesh Bhatt acquired 2,082 shares of common stock following the completion of a business combination with Sonnet BioTherapeutics Holdings, Inc.
Hyperliquid Strategies Director Lawrence E. Leibowitz received 39,800 shares of common stock following a business combination.
Hyperliquid Strategies CEO David Ira Schamis received 95,520 shares of common stock following the company's business combination with Sonnet BioTherapeutics Holdings, Inc.
Jeffrey Tuder, a director of Hyperliquid Strategies Inc., indirectly acquired 8,188 shares of common stock and 16,000 warrants through Tremson Capital Management, LLC following the company's business combination.
Hyperliquid Strategies Inc.'s CFO, Brett Douglas Beldner, acquired 31,840 shares of common stock following a business combination completed on December 2, 2025.
Hyperliquid Strategies Inc. has filed a Form 425 communication regarding Sonnet BioTherapeutics Holdings, Inc. on November 18, 2025.
Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting of stockholders to allow more time for voting on its proposed business combination with Hyperliquid Strategies Inc.